RANI Insider Trading

Insider Ownership Percentage: 53.30%
Insider Buying (Last 12 Months): $76,550.00
Insider Selling (Last 12 Months): $20,730,785.65

Rani Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Rani Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rani Therapeutics Share Price & Price History

Current Price: $2.03
Price Change: Price Decrease of -0.02 (-0.98%)
As of 11/21/2024 01:00 AM ET

This chart shows the closing price history over time for RANI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Rani Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/15/2024South Cone Investments LimitedMajor ShareholderSell3,829,360$2.65$10,147,804.008,302,194View SEC Filing Icon  
12/6/2023Talat ImranCEOBuy10,000$2.27$22,700.00484,455View SEC Filing Icon  
12/4/2023Talat ImranCEOBuy5,000$2.57$12,850.00474,455View SEC Filing Icon  
11/29/2023Talat ImranCEOBuy20,000$2.05$41,000.00469,455View SEC Filing Icon  
11/24/2023Cortes Isidoro Alfonso QuirogaMajor ShareholderSell5,265,165$2.01$10,582,981.658,400View SEC Filing Icon  
11/16/2023Maulik NanavatyDirectorBuy500$1.98$990.00500View SEC Filing Icon  
5/11/2023South Cone Investments LimitedMajor ShareholderBuy2,610$3.87$10,100.706,863,744View SEC Filing Icon  
5/8/2023South Cone Investments LimitedMajor ShareholderBuy4,420$4.46$19,713.206,861,134View SEC Filing Icon  
5/3/2023South Cone Investments LimitedMajor ShareholderBuy2,040$4.81$9,812.406,856,714View SEC Filing Icon  
4/28/2023South Cone Investments LimitedMajor ShareholderBuy2,173$4.71$10,234.836,854,674View SEC Filing Icon  
4/24/2023South Cone Investments LimitedMajor ShareholderBuy4,280$4.67$19,987.606,848,078View SEC Filing Icon  
4/20/2023South Cone Investments LimitedMajor ShareholderBuy1,850$5.32$9,842.006,839,698View SEC Filing Icon  
4/18/2023South Cone Investments LimitedMajor ShareholderBuy1,850$5.37$9,934.506,837,848View SEC Filing Icon  
4/14/2023South Cone Investments LimitedMajor ShareholderBuy1,901$5.27$10,018.276,835,998View SEC Filing Icon  
4/12/2023South Cone Investments LimitedMajor ShareholderBuy3,577$5.48$19,601.966,833,207View SEC Filing Icon  
4/10/2023South Cone Investments LimitedMajor ShareholderBuy1,923$5.07$9,749.616,827,865View SEC Filing Icon  
4/5/2023South Cone Investments LimitedMajor ShareholderBuy7,280$5.49$39,967.206,818,391View SEC Filing Icon  
4/3/2023South Cone Investments LimitedMajor ShareholderBuy3,587$5.23$18,760.016,806,695View SEC Filing Icon  
3/30/2023South Cone Investments LimitedMajor ShareholderBuy12,230$4.79$58,581.706,802,357View SEC Filing Icon  
3/28/2023South Cone Investments LimitedMajor ShareholderBuy3,510$5.49$19,269.906,790,127View SEC Filing Icon  
3/20/2023South Cone Investments LimitedMajor ShareholderBuy532$6.29$3,346.286,783,387View SEC Filing Icon  
3/16/2023South Cone Investments LimitedMajor ShareholderBuy1,325$6.07$8,042.756,779,875View SEC Filing Icon  
3/13/2023South Cone Investments LimitedMajor ShareholderBuy2,463$6.14$15,122.826,778,550View SEC Filing Icon  
3/8/2023South Cone Investments LimitedMajor ShareholderBuy1,702$6.58$11,199.166,772,357View SEC Filing Icon  
3/6/2023South Cone Investments LimitedMajor ShareholderBuy1,100$6.39$7,029.006,770,655View SEC Filing Icon  
3/2/2023South Cone Investments LimitedMajor ShareholderBuy3,900$6.31$24,609.006,769,555View SEC Filing Icon  
2/27/2023South Cone Investments LimitedMajor ShareholderBuy3,541$6.30$22,308.306,764,944View SEC Filing Icon  
2/24/2023South Cone Investments LimitedMajor ShareholderBuy5,451$6.09$33,196.596,761,403View SEC Filing Icon  
2/21/2023South Cone Investments LimitedMajor ShareholderBuy3,080$5.94$18,295.206,754,952View SEC Filing Icon  
2/16/2023South Cone Investments LimitedMajor ShareholderBuy9,500$5.49$52,155.006,743,404View SEC Filing Icon  
2/14/2023South Cone Investments LimitedMajor ShareholderBuy9,250$5.25$48,562.506,723,904View SEC Filing Icon  
12/28/2022South Cone Investments LimitedMajor ShareholderBuy9,157$5.58$51,096.066,697,454View SEC Filing Icon  
12/19/2022South Cone Investments LimitedMajor ShareholderBuy6,900$7.43$51,267.006,688,297View SEC Filing Icon  
12/16/2022South Cone Investments LimitedMajor ShareholderBuy6,400$7.76$49,664.006,681,397View SEC Filing Icon  
12/12/2022South Cone Investments LimitedMajor ShareholderBuy12,500$8.04$100,500.006,646,628View SEC Filing Icon  
12/9/2022South Cone Investments LimitedMajor ShareholderBuy12,345$8.01$98,883.456,634,128View SEC Filing Icon  
12/7/2022South Cone Investments LimitedMajor ShareholderBuy600$7.94$4,764.006,609,588View SEC Filing Icon  
12/5/2022South Cone Investments LimitedMajor ShareholderBuy12,195$7.97$97,194.156,596,488View SEC Filing Icon  
12/2/2022South Cone Investments LimitedMajor ShareholderBuy9,819$8.16$80,123.046,584,293View SEC Filing Icon  
11/30/2022South Cone Investments LimitedMajor ShareholderBuy8,000$7.93$63,440.006,574,272View SEC Filing Icon  
11/28/2022South Cone Investments LimitedMajor ShareholderBuy3,720$7.95$29,574.006,566,272View SEC Filing Icon  
11/25/2022South Cone Investments LimitedMajor ShareholderBuy800$7.84$6,272.006,562,552View SEC Filing Icon  
11/23/2022South Cone Investments LimitedMajor ShareholderBuy3,396$7.84$26,624.646,561,752View SEC Filing Icon  
11/21/2022South Cone Investments LimitedMajor ShareholderBuy3,200$7.87$25,184.006,545,856View SEC Filing Icon  
11/18/2022South Cone Investments LimitedMajor ShareholderBuy13,300$7.49$99,617.006,542,656View SEC Filing Icon  
11/2/2022Cortes Isidoro Alfonso QuirogaMajor ShareholderBuy25,197$6.31$158,993.075,247,786View SEC Filing Icon  
10/31/2022Cortes Isidoro Alfonso QuirogaMajor ShareholderBuy16,523$6.11$100,955.535,218,821View SEC Filing Icon  
8/17/2022Mir A ImranDirectorSell80,252$10.64$853,881.2866,445View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Rani Therapeutics (NASDAQ:RANI)

30.19% of Rani Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RANI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Rani Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2024Geode Capital Management LLC172,261$0.37M0.0%+14.3%0.323%Search for SEC Filing on Google Icon
11/15/2024United Services Automobile Association302,743$0.65M0.0%-3.0%0.567%Search for SEC Filing on Google Icon
11/15/2024Stifel Financial Corp269,768$0.58M0.0%+100.4%0.505%Search for SEC Filing on Google Icon
11/8/2024King Luther Capital Management Corp81,129$0.18M0.0%+44.5%0.152%Search for SEC Filing on Google Icon
8/14/2024Marshall Wace LLP21,247$81K0.0%N/A0.042%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC21,700$82K0.0%-69.1%0.043%Search for SEC Filing on Google Icon
8/7/2024United Services Automobile Association312,095$1.19M0.0%-35.2%0.619%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.685,303$2.13M0.0%+2.5%1.366%Search for SEC Filing on Google Icon
2/14/2024Alpha Square Group S LLC58,946$0.20M0.2%-32.2%0.118%Search for SEC Filing on Google Icon
8/10/2023King Luther Capital Management Corp56,129$0.23M0.0%N/A0.113%Search for SEC Filing on Google Icon
8/4/2023Choreo LLC19,813$82K0.0%-20.2%0.040%Search for SEC Filing on Google Icon
5/11/2023Icon Wealth Partners LLC12,757$66K0.0%N/A0.026%Search for SEC Filing on Google Icon
5/11/2023Alphabet Inc.448,492$2.31M0.1%-12.1%0.908%Search for SEC Filing on Google Icon
2/8/2023Prime Capital Investment Advisors LLC33,502$0.20M0.0%N/A0.068%Search for SEC Filing on Google Icon
11/18/2022TPB Wealth Advisors48,129$0.46M0.2%-33.0%0.098%Search for SEC Filing on Google Icon
11/16/2022Alphabet Inc.714,471$6.85M0.3%N/A1.453%Search for SEC Filing on Google Icon
11/3/2022Motco48,129$0.46M0.0%N/A0.098%Search for SEC Filing on Google Icon
10/28/2022Lafayette Investments Inc.19,893$0.19M0.1%N/A0.040%Search for SEC Filing on Google Icon
10/17/2022Canton Hathaway LLC16,200$0.16M0.1%+88.4%0.033%Search for SEC Filing on Google Icon
10/14/2022Iowa State Bank18,862$0.18M0.1%N/A0.038%Search for SEC Filing on Google Icon
8/8/2022Islay Capital Management LLC9,611$99K0.1%N/A0.020%Search for SEC Filing on Google Icon
8/8/2022Crossvault Capital Management LLC14,285$0.15M0.1%N/A0.029%Search for SEC Filing on Google Icon
7/29/2022Aspireon Wealth Advisors71,811$0.74M0.3%N/A0.146%Search for SEC Filing on Google Icon
7/20/2022Canton Hathaway LLC8,600$89K0.0%N/A0.017%Search for SEC Filing on Google Icon
6/15/2022Lasry Marc62,828$0.85M0.4%N/A0.128%Search for SEC Filing on Google Icon
5/17/2022Lasry Marc62,828$0.85M0.4%N/A0.128%Search for SEC Filing on Google Icon
5/13/2022United Services Automobile Association481,300$6.50M0.1%N/A0.979%Search for SEC Filing on Google Icon
2/3/2022Advisor Group Holdings Inc.21,072$0.34M0.0%N/A0.043%Search for SEC Filing on Google Icon
1/6/2022Canton Hathaway LLC5,000$82K0.0%-50.0%0.010%Search for SEC Filing on Google Icon
11/16/2021Squarepoint Ops LLC50,000$0.89M0.0%N/A0.102%Search for SEC Filing on Google Icon
11/15/2021Caas Capital Management LP75,000$1.34M0.0%N/A0.153%Search for SEC Filing on Google Icon
11/10/2021Goldman Sachs Group Inc.60,649$1.08M0.0%N/A0.124%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Rani Therapeutics logo
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Read More on Rani Therapeutics

Today's Range

Now: $2.03
Low: $2.01
High: $2.08

50 Day Range

MA: $2.34
Low: $2.02
High: $3.18

52 Week Range

Now: $2.03
Low: $1.90
High: $8.75

Volume

323,938 shs

Average Volume

549,488 shs

Market Capitalization

$108.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11

Who are the company insiders with the largest holdings of Rani Therapeutics?

Rani Therapeutics' top insider shareholders include:
  1. South Cone Investments Limited (Major Shareholder)
  2. Talat Imran (CEO)
  3. Cortes Isidoro Alfonso Quiroga (Major Shareholder)
  4. Maulik Nanavaty (Director)
Learn More about top insider investors at Rani Therapeutics.

Who are the major institutional investors of Rani Therapeutics?

Rani Therapeutics' top institutional investors include:
  1. United Services Automobile Association — 0.57%
  2. Stifel Financial Corp — 0.51%
  3. Geode Capital Management LLC — 0.32%
  4. King Luther Capital Management Corp — 0.15%
  5. Belvedere Trading LLC — 0.00%
Learn More about top institutional investors of Rani Therapeutics stock.

Which major investors are selling Rani Therapeutics stock?

During the last quarter, RANI stock was sold by these institutional investors:
  1. United Services Automobile Association
  2. Belvedere Trading LLC
During the previous year, company insiders that have sold Rani Therapeutics company stock include:
  1. South Cone Investments Limited (Major Shareholder)
  2. Talat Imran (CEO)
Learn More investors selling Rani Therapeutics stock.

Which major investors are buying Rani Therapeutics stock?

During the previous quarter, RANI stock was acquired by institutional investors including:
  1. Stifel Financial Corp
  2. King Luther Capital Management Corp
  3. Geode Capital Management LLC
Within the last year, these company insiders have bought Rani Therapeutics stock:
  1. South Cone Investments Limited (Major Shareholder)
  2. Talat Imran (CEO)
  3. Cortes Isidoro Alfonso Quiroga (Major Shareholder)
Learn More investors buying Rani Therapeutics stock.